- Conditions
- Hemophilia A or B With Inhibitors, Hemophilia A, Hemophilia B
- Interventions
- Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 4 Years to 65 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced May 22, 2026, 3:53 AM EDT